AMD3100 [plerixafor] with busulfan, fludarabine and thymoglobulin for allogeneic stem cell transplantation for acute myelogenous leukemia [acute myeloid leukaemia; AML] and myelodysplastic syndromes

Trial Profile

AMD3100 [plerixafor] with busulfan, fludarabine and thymoglobulin for allogeneic stem cell transplantation for acute myelogenous leukemia [acute myeloid leukaemia; AML] and myelodysplastic syndromes

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2014

At a glance

  • Drugs Plerixafor (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AnorMED; Sanofi
  • Most Recent Events

    • 14 Nov 2007 Status changed from initiated to withdrawn prior to recruitment.
    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top